CClinicalTrials.gg
RecruitingNCT06647784LAT&PRONEUpdated May 15, 2025

Lateral Positioning and Prone Positioning in ARDS Patients

An interventional study of pulmonary aeration in supine and ventral decubitus in ARDS, sponsored by Centre Hospitalier de Bastia. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Centre Hospitalier de Bastia · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jan 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Lateral (30°) and alternating positioning (change of side every 30 minutes) carried out on specific beds, could be an alternative or complement to prone positioning (PP) in ARDS patients. The combination of lateralization in prone position has not been studied. The dynamic created by lateralization could allow better overall ventilation during PP, thus making it possible to further improve oxygenation. The main objective of this prospective, bicentric, open, single group study with repeated measures will be to demonstrate that the addition of repeated 30-minute periods of 30° lateralization improves pulmonary aeration in the supine and prone positions in patients with moderate to severe ARDS.

Read the detailed description

Primary objective: assessment of the distribution of tidal volume after lateralization and according to the position (supine position SP, prone position, PP) by measuring global and regional changes (4 regions of interest from the retrosternal region to the prevertebral region) of pulmonary aeration assessed by electrical impedance tomography (EIT). The primary endpoint will be the change in pulmonary aeration after lateralization in SP (T2) and in PP (T5) estimated by the change in end-expiratory lung impedance (EELI) = [ΔEELI x (VT/ΔZ)] where VT is the tidal volume and ΔZ is the impedance change.

Main secondary objective: assessment of perfusion and gas exchange after each period of lateralization compared to the baseline period in supine position (baseline SP) and in ventral position (baseline PP) (endpoints: PaO2/FiO2 and PaCO2)

Other secondary objectives:

  • Evaluation of the percentage of patients who, at the end of the period of lateralization in supine position (T2), have a PaO2/FiO2 ratio > 150
  • Comparisons baseline SP with baseline PP, PP 6 hours, PP and lateral positioning (LP) 12 hours and return to supine position since 1 hour (End) for pulmonary aeration, gas exchange and ventilatory parameters (endpoints: PaO2/FiO2 and PaCO2, (EELI) = [ΔEELI x (VT/ΔZ)], plateau pressure, driving pressure).
  • Baseline PP comparisons with PP 6 hours, PP and lateral positioning (LP) 12 hours and return to supine position since 1 hour (End) for pulmonary aeration, gas exchange and ventilatory parameters (endpoints: PaO2/FiO2 and PaCO2, (EELI) = [ΔEELI x (VT/ΔZ)], plateau pressure, driving pressure)
  • LP comparisons in SP for 6 hours with LP in PP for 12 hours for pulmonary aeration, gas exchange and ventilatory parameters (endpoints: PaO2/FiO2 and PaCO2, (EELI) = [ΔEELI x (VT/ΔZ)], plateau pressure, driving pressure)
  • LP comparisons in PP for 12 hours with return to supine position since 1 hour (End) for pulmonary aeration, gas exchange and ventilatory parameters (endpoints: PaO2/FiO2 and PaCO2, (EELI) = [ΔEELI x (VT/ΔZ)], plateau pressure, driving pressure) : PaO2/FiO2 and PaCO2, (EELI) = [ΔEELI x (VT/ΔZ)], plateau pressure, driving pressure)
  • Evaluate the adverse effects related to the use of lateral positioning.
02

Conditions studied

  • ARDS

Keywords

  • ARDS
  • Pulmonary aeration
  • Supine
  • prone position
  • lateralization
03

In context

Lead sponsor

This is the only study on the registry with Centre Hospitalier de Bastia as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age of at least 18 years
  • ARDS evolving for less than 5 days with a PaO2/FiO2 ratio (P/F ratio) \< 150 after optimization of PEEP (P/V curve, R/I ratio), curarization and without prior use of the PP since orotracheal intubation.
  • Obtained written consent of the patient, one of his relatives or the previously designated trusted person. As soon as possible, the patient will be informed and his written consent will be obtained
  • Beneficiary of health insurance coverage
  • Possibility of participating in any other studies whose evaluation criteria do not interfere with those of the study

Non-inclusion criteria:

Patients with at least one of the following criteria will not be eligible:

  • Refusal to participate
  • Pregnant, parturient or breastfeeding women
  • Intracranial pressure > 30 mm Hg or cerebral perfusion pressure \< 60 mmHg
  • Severe chronic respiratory disease with oxygen therapy or mechanical ventilation at home (except CPAP/BIPAP for obstructive sleep apnea)
  • Chronic interstitial lung diseases
  • Patients on ECMO
  • Weight > 100 kg
  • Severe liver disease Child-Pugh score 12-15
  • Pneumothorax
  • SAPS II score > 75 at inclusion
  • Unstable spinal fracture
  • Contraindications to EIT (pacemaker, implantable defibrillator, skin lesions between the 4th and 5th ribs).
  • Withdrawal (except for ECMO) or witholding treatment decision
  • Any other reason which, according to the investigator, could interfere with the evaluation of the study objectives
  • Person under legal protection measure (guardianship, curatorship, etc.)
  • Person deprived of liberty by a judiciary or administrative decision

Exclusion criteria

Exclusion criteria:

  • Patients who will be unable to complete the 25-hour intervention due to worsening requiring ECMO, death or organizational problems will be excluded from the analysis.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Lateral and alterning positioning

    Baseline assessment in SP followed by repeated 30-minute lateral decubitus sessions on each side (with a 30° inclination) with a right/left alternation (total duration, 1 hour). During this period, the upper part of the bed will be inclined by 30°. The patients will then be positioned in prone position for a period of 6 hours after which, the same alternating lateral decubitus pattern (repeated 30-minute lateral decubitus sessions on each side with a right/left alternation ) will be applied for 12 hours while the patient is still in prone position. After turning back to the supine position, a 1-hour observation period will be respected before the last measurements are taken. The total duration of the intervention will thus be 20 hours.

    Other: pulmonary aeration in supine and ventral decubitus

Interventions

  • Otherpulmonary aeration in supine and ventral decubitus

    The addition of repeated periods of 30 minutes of lateralization of 30° amplitude in dorsal decubitus and in ventral decubitus in patients with moderate to severe ARDS. Included patients will benefit from sessions of lateral decubitus for 30 minutes on each side (with an inclination of 30°) with alternation right/left (total one hour). During this period, the upper part of the bed will be inclined by 30°. Patients will then be positioned in strict prone position for a period of 6 hours after which, the same pattern of alternating lateral decubitus will be applied for 12 hours while the patient is still in the prone position. After reversal in supine position, an observation period of 1 hour will be respected before carrying out the last measurements. The total duration of the intervention will be 20 hours.

06

What researchers measure

Primary outcomes

  1. modification of pulmonary aeration

    Evaluation of the distribution of tidal volume after lateralization and according to the position (supine: SP, prone: PP) by measuring global changes and regional (4 regions of interest from the retro-sternal region to the pre-vertebral region) of ventilation lung assessed by electrical impedance tomography (EIT).The primary endpoint will be the change in pulmonary aeration after lateralization in SP (T2) and in PP (T5) estimated by the variation in end-expiration pulmonary impedance (EELI) = \[ΔEELI x (VT/ΔZ)\] where VT is the tidal volume and ΔZ the impedance variation.

    Time frame: Up to 25 hours.

Secondary outcomes

  1. Assessment of gas exchange

    Assessment of gas exchange (by blood gas analyses) after each each lateralization period compared with the baseline period in dorsal position (SP) and prone position (baseline PP) (endpoints: PaO2/FiO2 and PaCO2)

    Time frame: Up to 25 hours

  2. Assessment of lung perfusion

    Assessment of lung perfusion by EIT (administration of 10 ml 7.5% hypertonic saline during an expiratory pause)

    Time frame: Up to 25 hours

Other outcomes

  1. Estimated PaO2/FiO2 ratio > 150

    Evaluation of the percentage of patients with a PaO2/FiO2 ratio \> 150 at the end of the supine lateralization period

    Time frame: Up to 25 hours

  2. Measurement of lung aeration

    Comparisons of : baseline SP with baseline PP, 6-hours PP, PP and lateral positioning (LP) 12h and return to supine for 1h (End), baseline PP with PP 6 hours, PP and lateral positioning (LP) 12h, LP in SP for 6h with LP in PP for 12h and LP comparisons in PP for 12h with return to supine for 1h (End) for pulmonary aeration, (endpoints: PaO2/FiO2 and PaCO2, (EELI) = \[ΔEELI x (VT/ΔZ)\], plateau pressure, driving pressure).

    Time frame: Up to 25 hours

  3. Gas exchange assessment

    Comparisons of baseline SP with baseline PP, 6-hours PP, PP and lateral positioning (LP) 12h and return to supine for 1h (End), baseline PP with PP 6 hours, PP and lateral positioning (LP) 12h, LP in SP for 6h with LP in PP for 12h and LP comparisons in PP for 12h with return to supine for 1h (End) for gas exchanges (endpoints: PaO2/FiO2 and PaCO2).

    Time frame: Up to 25 hours

  4. Measurement of ventilatory parameters

    Comparisons of baseline SP with baseline PP, 6-hours PP, PP and lateral positioning (LP) 12h and return to supine for 1h (End), baseline PP with PP 6 hours, PP and lateral positioning (LP) 12h, LP in SP for 6h with LP in PP for 12h and LP comparisons in PP for 12h with return to supine for 1h (End) for ventilatory parameters (plateau pressure, driving pressure, compliance, elastance).

    Time frame: Up to 25 hours

  5. Adverse effects

    Evaluate adverse effects associated with the use of lateral positioning.

    Time frame: Up to 25 hours

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Only IPD used in the results publication

Supporting information: Study protocol, Icf, Csr

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06647784
Lead sponsor
Centre Hospitalier de Bastia
Collaborators
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Responsible party
Sponsor
First posted
Oct 18, 2024
Start date
Nov 26, 2024
Primary completion
Jan 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
May 15, 2025

Study contacts

Laurent Papazian, MD,PHD
Contact
laurent.papazian@ch-bastia.fr
0495591039
Antoine Faure, PH
Contact
antoine.faure@ch-bastia.fr
0495591111
laurent papazian, MD,PHD
study director · Bastia General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion